Med-tech deals are up 49.01% year over year, with the industry raising $9.83 billion through September in 2023, up from $6.59 billion in the same time frame last year. The number of deals, meanwhile, has decreased from 1,510 through Q3 2022 to 1,278 this year.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Brainsway, Delcath, GE Healthcare, Neuonetics, Nexalin.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bonesupport, Burning Rock Biotech, Establishment Labs.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Endonovo Therapeutics, Foundation Medicine, Infobionic, Medtronic.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allurion, Edwards, Glucotrack, Guerbet, Illumina, Inspiremd, Mindray, T2 Biosystems.
Derek Sham, founder and CEO, of Toronto, Ontario-based Cosm Medical Corp. reported filing for patent protection for devices, systems and methods for vaginal therapeutics. He reported on a range of surgical treatment options for pelvic organ prolapse (POP) and urinary incontinence (UI) as well as non-surgical treatments exist for POP and UI.
No one is looking in the rearview mirror at Medtronic plc as a fresh U.S. FDA approval for the next generation version of its intrathecal drug delivery system allows the company to leave behind a spate of problems associated with its Sychromed II device. The device delivers medication directly to the fluid surrounding the spinal cord via a small catheter positioned to deposit the drug at the site of most severe pain. The targeted delivery improves management of chronic and cancer-related pain as well as management of severe spasticity without use of systemic opioids.
RSS
